GB201800546D0 - Treatment - Google Patents

Treatment

Info

Publication number
GB201800546D0
GB201800546D0 GBGB1800546.2A GB201800546A GB201800546D0 GB 201800546 D0 GB201800546 D0 GB 201800546D0 GB 201800546 A GB201800546 A GB 201800546A GB 201800546 D0 GB201800546 D0 GB 201800546D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1800546.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Priority to GBGB1800546.2A priority Critical patent/GB201800546D0/en
Publication of GB201800546D0 publication Critical patent/GB201800546D0/en
Priority to SI201930833T priority patent/SI3737423T1/sl
Priority to BR112020014191A priority patent/BR112020014191A2/pt
Priority to EA202091655A priority patent/EA202091655A1/ru
Priority to EP19701018.4A priority patent/EP3737423B1/en
Priority to AU2019206314A priority patent/AU2019206314B2/en
Priority to KR1020207023349A priority patent/KR102786552B1/ko
Priority to US16/961,857 priority patent/US11680276B2/en
Priority to FIEP19701018.4T priority patent/FI3737423T3/fi
Priority to SM20240410T priority patent/SMT202400410T1/it
Priority to PL19701018.4T priority patent/PL3737423T3/pl
Priority to HUE19701018A priority patent/HUE068987T2/hu
Priority to RS20241186A priority patent/RS66227B1/sr
Priority to PT197010184T priority patent/PT3737423T/pt
Priority to CA3088079A priority patent/CA3088079A1/en
Priority to DK19701018.4T priority patent/DK3737423T3/da
Priority to JP2020538584A priority patent/JP7289306B2/ja
Priority to CN201980018443.4A priority patent/CN111936172A/zh
Priority to MX2020007366A priority patent/MX2020007366A/es
Priority to HRP20241483TT priority patent/HRP20241483T1/hr
Priority to ES19701018T priority patent/ES2988499T3/es
Priority to NZ766316A priority patent/NZ766316B2/en
Priority to LTEPPCT/GB2019/050092T priority patent/LT3737423T/lt
Priority to SG11202006618PA priority patent/SG11202006618PA/en
Priority to PCT/GB2019/050092 priority patent/WO2019138250A1/en
Priority to PH12020551071A priority patent/PH12020551071A1/en
Priority to IL275985A priority patent/IL275985A/en
Priority to US18/336,409 priority patent/US12467066B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1800546.2A 2018-01-12 2018-01-12 Treatment Ceased GB201800546D0 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
GBGB1800546.2A GB201800546D0 (en) 2018-01-12 2018-01-12 Treatment
PCT/GB2019/050092 WO2019138250A1 (en) 2018-01-12 2019-01-14 Compositions and methods for treating retinal disorders
RS20241186A RS66227B1 (sr) 2018-01-12 2019-01-14 Kompozicije i postupci za lečenje poremećaja mrežnjače
CA3088079A CA3088079A1 (en) 2018-01-12 2019-01-14 Compositions and methods for treating retinal disorders
EA202091655A EA202091655A1 (ru) 2018-01-12 2019-01-14 Композиции и способы лечения нарушений сетчатки
EP19701018.4A EP3737423B1 (en) 2018-01-12 2019-01-14 Compositions and methods for treating retinal disorders
AU2019206314A AU2019206314B2 (en) 2018-01-12 2019-01-14 Compositions and methods for treating retinal disorders
KR1020207023349A KR102786552B1 (ko) 2018-01-12 2019-01-14 망막 질환 치료를 위한 조성물 및 방법
US16/961,857 US11680276B2 (en) 2018-01-12 2019-01-14 Compositions and methods for treating retinal disorders
FIEP19701018.4T FI3737423T3 (fi) 2018-01-12 2019-01-14 Koostumuksia ja menetelmiä verkkokalvon häiriöiden hoitoon
SM20240410T SMT202400410T1 (it) 2018-01-12 2019-01-14 Composizioni e metodi per il trattamento delle patologie retiniche
PL19701018.4T PL3737423T3 (pl) 2018-01-12 2019-01-14 Kompozycje i sposoby leczenia zaburzeń siatkówki
HUE19701018A HUE068987T2 (hu) 2018-01-12 2019-01-14 Készítmények és módszerek a retina rendellenességeinek kezelésére
SI201930833T SI3737423T1 (sl) 2018-01-12 2019-01-14 Sestavki in postopki za zdravljenje motenj mrežnice
PT197010184T PT3737423T (pt) 2018-01-12 2019-01-14 Composições e métodos para tratamento de distúrbios da retina
BR112020014191A BR112020014191A2 (pt) 2018-01-12 2019-01-14 Unidade de controle transcricional (uct), construção de expressão, vetor, célula hospedeira, composição farmacêutica, uso de um vetor, método para tratamento ou prevenção de distúrbios da retina e vetores para uso
DK19701018.4T DK3737423T3 (da) 2018-01-12 2019-01-14 Sammensætninger og fremgangsmåder til behandling af nethindelidelser
JP2020538584A JP7289306B2 (ja) 2018-01-12 2019-01-14 網膜障害を治療するための組成物及び方法
CN201980018443.4A CN111936172A (zh) 2018-01-12 2019-01-14 用于治疗视网膜病症的组合物和方法
MX2020007366A MX2020007366A (es) 2018-01-12 2019-01-14 Composiciones y metodos para tratar trastornos de la retina.
HRP20241483TT HRP20241483T1 (hr) 2018-01-12 2019-01-14 Sastavi i postupci za liječenje poremećaja mrežnice
ES19701018T ES2988499T3 (es) 2018-01-12 2019-01-14 Composiciones y métodos para tratar trastornos de la retina
NZ766316A NZ766316B2 (en) 2019-01-14 Compositions and methods for treating retinal disorders
LTEPPCT/GB2019/050092T LT3737423T (lt) 2018-01-12 2019-01-14 Kompozicijos ir būdai, skirti tinklainės sutrikimų gydymui
SG11202006618PA SG11202006618PA (en) 2018-01-12 2019-01-14 Compositions and methods for treating retinal disorders
PH12020551071A PH12020551071A1 (en) 2018-01-12 2020-07-10 Compositions and methods for treating retinal disorders
IL275985A IL275985A (en) 2018-01-12 2020-07-12 Preparations and methods for the treatment of retinal disorders
US18/336,409 US12467066B2 (en) 2018-01-12 2023-06-16 Compositions and methods for treating retinal disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1800546.2A GB201800546D0 (en) 2018-01-12 2018-01-12 Treatment

Publications (1)

Publication Number Publication Date
GB201800546D0 true GB201800546D0 (en) 2018-02-28

Family

ID=61256183

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1800546.2A Ceased GB201800546D0 (en) 2018-01-12 2018-01-12 Treatment

Country Status (26)

Country Link
US (2) US11680276B2 (cg-RX-API-DMAC7.html)
EP (1) EP3737423B1 (cg-RX-API-DMAC7.html)
JP (1) JP7289306B2 (cg-RX-API-DMAC7.html)
KR (1) KR102786552B1 (cg-RX-API-DMAC7.html)
CN (1) CN111936172A (cg-RX-API-DMAC7.html)
AU (1) AU2019206314B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014191A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088079A1 (cg-RX-API-DMAC7.html)
DK (1) DK3737423T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091655A1 (cg-RX-API-DMAC7.html)
ES (1) ES2988499T3 (cg-RX-API-DMAC7.html)
FI (1) FI3737423T3 (cg-RX-API-DMAC7.html)
GB (1) GB201800546D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20241483T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068987T2 (cg-RX-API-DMAC7.html)
IL (1) IL275985A (cg-RX-API-DMAC7.html)
LT (1) LT3737423T (cg-RX-API-DMAC7.html)
MX (1) MX2020007366A (cg-RX-API-DMAC7.html)
PH (1) PH12020551071A1 (cg-RX-API-DMAC7.html)
PL (1) PL3737423T3 (cg-RX-API-DMAC7.html)
PT (1) PT3737423T (cg-RX-API-DMAC7.html)
RS (1) RS66227B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006618PA (cg-RX-API-DMAC7.html)
SI (1) SI3737423T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400410T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019138250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906815A1 (en) 2013-03-15 2014-09-18 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
GB2584664B (en) * 2019-06-10 2023-05-24 Newcells Biotech Ltd Improved retinal organoids and methods of making the same
CN113025616B (zh) * 2021-04-21 2023-05-02 中国热带农业科学院橡胶研究所 一种橡胶树泛素基因启动子proHbUBI2及其克隆与应用
WO2022246089A1 (en) * 2021-05-20 2022-11-24 Artema Therapeutics, Inc. Kcnv2 variants and their use
CA3225080A1 (en) * 2021-07-14 2023-01-19 Anastasios GEORGIADIS Kcnv2 gene therapy
WO2023039175A2 (en) * 2021-09-09 2023-03-16 Applied Genetic Technologies Corporation Predictors of achromatopsia treatment efficacy
WO2026150224A1 (en) 2024-12-30 2026-07-16 MeiraGTx Ocular UK Limited Modified adeno-associated virus (aav) viral capsid proteins and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097538A4 (en) * 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
US20120172419A1 (en) * 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
CN103608455B (zh) * 2011-01-07 2019-01-15 应用遗传科技公司 用于治疗色盲和其它疾病的启动子、表达盒、载体、药盒和方法
ES2822551T3 (es) * 2014-03-17 2021-05-04 Adverum Biotechnologies Inc Composiciones y métodos para la expresión génica mejorada en células de los conos
FI3265178T3 (fi) * 2015-03-02 2026-08-03 Adverum Biotechnologies Inc Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin
WO2017144080A1 (en) * 2016-02-23 2017-08-31 Eyeserv Gmbh Gene therapy for the treatment of a disease of retinal cone cells

Also Published As

Publication number Publication date
SI3737423T1 (sl) 2025-03-31
FI3737423T3 (fi) 2024-11-02
DK3737423T3 (da) 2024-10-21
PH12020551071A1 (en) 2021-09-06
ES2988499T3 (es) 2024-11-20
US20200392536A1 (en) 2020-12-17
EP3737423A1 (en) 2020-11-18
US11680276B2 (en) 2023-06-20
EA202091655A1 (ru) 2020-11-20
SMT202400410T1 (it) 2025-01-14
CN111936172A (zh) 2020-11-13
US12467066B2 (en) 2025-11-11
SG11202006618PA (en) 2020-08-28
KR20200141435A (ko) 2020-12-18
MX2020007366A (es) 2020-09-03
PT3737423T (pt) 2024-10-03
AU2019206314B2 (en) 2025-02-13
PL3737423T3 (pl) 2025-01-27
CA3088079A1 (en) 2019-07-18
IL275985A (en) 2020-08-31
HRP20241483T1 (hr) 2025-01-03
WO2019138250A1 (en) 2019-07-18
HUE068987T2 (hu) 2025-02-28
AU2019206314A1 (en) 2020-08-13
JP2021510301A (ja) 2021-04-22
NZ766316A (en) 2024-05-31
RS66227B1 (sr) 2024-12-31
EP3737423B1 (en) 2024-09-18
US20240067989A1 (en) 2024-02-29
JP7289306B2 (ja) 2023-06-09
BR112020014191A2 (pt) 2022-02-22
LT3737423T (lt) 2024-11-25
KR102786552B1 (ko) 2025-03-26

Similar Documents

Publication Publication Date Title
GB201804255D0 (en) Macrophage-based therapy
GB201813876D0 (en) Treatment
GB201800274D0 (en) Novel treatments
GB201819853D0 (en) Therapy
GB201916237D0 (en) Novel treatment
IL288937A (en) Improved treatment using eyp001
ZA202006321B (en) Treatments
PL3612475T3 (pl) Instalacja obróbkowa
GB201808564D0 (en) Treatments
SG11202102878TA (en) Treatment methods
SG11202102827YA (en) Treatment methods
GB201913988D0 (en) Novel treatment
GB201914296D0 (en) Treatment
GB201912365D0 (en) Treatment
GB201817385D0 (en) Therapy
GB201718985D0 (en) Treatment
GB201902579D0 (en) Treatment
PL3597169T3 (pl) Sauna
GB201814905D0 (en) Treatment
GB201912760D0 (en) Treatment
GB201912335D0 (en) Treatment
GB201911816D0 (en) Treatment
GB201911603D0 (en) Treatment
GB201910755D0 (en) Treatment
GB201904253D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)